SCHEMBL20164569

SCHEMBL20164569

OCCCNc1nc(Cl)nc2c(Cl)nc(Cl)nc12

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 4/20 0.41
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
RAD52 P43351 1/20 0.33
ADORA3 P0DMS8 1/20 0.32
ADORA1 P30542 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20164652 0.89 SLC29A1 (0.44) SLC29A1KMT2AMEN1HTTMAPT
SCHEMBL20164617 0.85 SLC29A1 (0.47) SLC29A1KMT2AMEN1HTTSMN1; SMN2
SCHEMBL20164645 0.85 SLC29A1 (0.51) SLC29A1KMT2AMEN1HTTSMN1; SMN2
SCHEMBL20164779 0.79 SLC29A1 (0.42) SLC29A1KMT2ALMNANPSR1RAD52
SCHEMBL20164638 0.74 SLC29A1 (0.54) SLC29A1KMT2AHTTLMNAMAPT
SCHEMBL20164431 0.74 SLC29A1 (0.46) SLC29A1KMT2AHTTMAPTPOLB
SCHEMBL12330861 0.72 TLR8 (0.46) SLC29A1KMT2AMEN1HTTSMN1; SMN2
SCHEMBL30733442 0.72 KMT2A (0.41) SLC29A1KMT2AMEN1HTTSMN1; SMN2
SCHEMBL26695833 0.72 KMT2A (0.41) SLC29A1KMT2AMEN1HTTSMN1; SMN2
SCHEMBL10005092 0.71 KMT2A (0.54) SLC29A1KMT2ASMN1; SMN2LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same MTNR1B, CHRM3, PER2 SLC29A1 4472/4885KMT2A 2456/4885MEN1 2683/4885
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same MTNR1B, PDE3A, CHRM3 SLC29A1 4518/4885KMT2A 2528/4885MEN1 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.